cgmp-manufacturing
(6)
RadioMedix and the cancer drugs that race the clock
A radioactive medicine has two jobs: find its target and arrive before its useful activity fades. RadioMedix has spent two decades working on both, from PET imaging to an investigational alpha therapy licensed to Sanofi.
The Molecule Is Promising. Can It Survive the Factory?
JOINN Biologics US sells a deceptively practical service: finding out early whether a brilliant biologic can be made, measured and supplied. Its Richmond team now applies that logic from antibody screening to a 2026 biosimilar partnership.
The quiet engineer keeping Takeda's medicine flowing
He does not develop the drug or run the ads. He makes sure the thing gets made, on spec, on time, batch after batch - across a network of factories Takeda does not own.
PranaX
PranaX is a Houston-based regenerative medicine biotechnology company developing stem cell-derived exosome products to counter aging, inflammation, and tissue damage. Built on exosome technology exclusively licensed from The University of Texas MD Anderson Cancer Center, PranaX operates an FDA-registered cGMP facility at the Levit Green life science campus and is bringing to market a physician-directed exosome wellness supplement (ExoWELL) and a personal exosome banking service (ExoSTORE). The company closed an oversubscribed $17M Series A in early 2026.
Corganics
Corganics is a Dallas-based life sciences company that makes scientifically formulated, physician-advised clinical CBD therapies sold exclusively through licensed healthcare professionals. Its broad-spectrum, THC-free products use Advanced Lipid Technology (A.L.T.) to improve bioavailability and are manufactured in cGMP-compliant, NSF-certified facilities with third-party testing and IRB-approved data. Founded in 2020 by pharmaceutical executives Chad Collins and Reggie Gatewood, the company aims to make CBD a trusted, clinic-grade therapy rather than a retail gamble.
Koji Tanabe
Koji Tanabe is the founder and CEO of I Peace, Inc., a Palo Alto and Kyoto biotech building an automated platform to mass-manufacture clinical-grade induced pluripotent stem cells (iPSCs). He earned his PhD in the Kyoto University lab of Nobel laureate Shinya Yamanaka and was a co-author of the landmark paper that first reported the creation of human iPS cells. After postdoctoral work at Stanford, he founded I Peace in 2015 with the goal of giving every person access to their own stem cells for therapy and longevity.